Clinical trial

The Pediatric Oncology Interventional Nutrition Therapy (POINT) Trial: A Pilot Study

Name
89377
Description
Nearly 60% of pediatric patients diagnosed with cancer develop malnutrition caused by a combination of disease burden, side effects of chemotherapy, and the intensity of cancer treatment. These patients are known to have an increased risk of infection, treatment-related toxicity, inferior clinical outcomes, and increased risk of mortality. Malnutrition may progress to cancer cachexia, characterized by anorexia, increased inflammation, decreased fat, and decreased muscle mass with subsequent weight loss, which is associated with decreased overall survival. The goal of the proposed research is to determine changes in body composition, weight status, and nutritional status between common nutrition interventions including oral nutrition supplements (ONS), appetite stimulants, and enteral nutrition (EN) among pediatric cancer patients. A secondary goal of this research is to utilize the findings to develop clinical nutrition guidelines for this patient population. The specific objective of the research proposed is to solve the lack of evidence to adequately treat nutritional deficits in the pediatric oncology population. Without this data, there is a lack of clinical consistency in the initiation and selection of appropriate nutrition interventions to provide a more definitive pathway of care. This study can help formulate a clinical guideline for this patient population before, during, and after treatment.
Trial arms
Trial start
2024-01-31
Estimated PCD
2024-12-01
Trial end
2025-07-01
Status
Recruiting
Phase
Early phase I
Treatment
Oral Nutrition Supplement
8oz (240mL) per dose at least once a day, but up to six times per day depending on estimated nutrient needs. The formula will equate to 1.0kcal/mL
Arms:
Oral Nutrition Supplements
Tube Feed
EN will have a feeding tube placed and started on tube feeds via a designated pump for overnight feeds, meeting at least 50% of estimated energy needs
Arms:
Enteral Nutrition
Cyproheptadine
0.25mg/kg/d divided BID. May titrate by 4mg increments to a max of 12mg/day.
Arms:
Appetite Stimulants
Dronabinol
5mg BID (before breakfast and lunch). May titrate by 2.5mg increments to max of 20mg/day
Arms:
Appetite Stimulants
Standard of Care
Diet education on high protein, high calorie food consumption
Arms:
Control
Size
45
Primary endpoint
Body Composition
Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months.
Body Composition
Baseline, at 3 and 6 months from baseline for control group. Those randomized will receive measurements at randomization and 1 & 3 months.
Eligibility criteria
Inclusion Criteria: * New diagnosis of pediatric cancer Exclusion Criteria: * Current use or history of enteral nutrition, oral supplement, or orexigenic/anorectic use.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 45, 'type': 'ESTIMATED'}}
Updated at
2024-02-05

1 organization

2 products

6 indications

Organization
Corey Hawes
Indication
Muscle Atrophy
Indication
Malnutrition
Indication
Pediatric
Product
Dronabinol